Why the study?
Little is known about sex-specific differences in prescription of lipid-lowering therapy and response to therapy in patients with heterozygous familial hypercholesterolemia.
Are there sex-specific differences in the prescription of lipid-lowering therapy and response to therapy in patients with familial hypercholesterolemia?
Are there sex-specific differences in the prescription of lipid-lowering therapy and response to therapy in patients with familial hypercholesterolemia?
eterozygous familial hypercholesterolemia (FH) is the most common genetic disorder with a prevalence of 1 in 311 and is associated with a high risk of premature cardiovascular disease (CVD). As an autosomal dominant condition, it affects men and women equally. However, little is known about sex-specific differences in prescription of lipidlowering therapy (LLT) and response to therapy in patients with FH.
No takes yet. Share an insight, caveat, or question.
Ryzhaya et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: